Search

Objectives: The incidence of tracheal cancer is low, few clinicians get much experience and the awareness may be low. Recent data on the treatment and outcome are limited. The aim of the present study was to present updated, national data on the incidence, characteristics, treatment and outcome for patients with tracheal cancer., Methods: All tracheal cancers registered at the Cancer Registry of Norway in 2000-2020 were extracted. The patient and tumour characteristics age, sex, stage, histology and treatment modality (surgery and radiotherapy) were examined. Overall, median and relative survival were estimated. Cox regression models were used to identify independent prognostic factors., Results: The 77 patients diagnosed with tracheal cancer equals a crude incidence rate and an age-standardized incidence rate of 0.075 and 0.046 per 100,000 per year respectively. The mean age was 63.8 years (range: 26-94). The numerical preponderance of men (n = 41) is not statistically significant. Eighteen patients (23.4%) were diagnosed in the localized stage. The 5-year overall survival was 31.7% [95% confidence interval (CI): 21.0-42.9], and in those treated with surgical resection or curative radiotherapy, it was 53.7% (95% CI: 26.1-75.0) and 37.8% (95% CI: 18.8-56.7), respectively. Age, histological type and treatment modality were identified as independent prognostic factors., Conclusions: Despite improved survival, the prognosis for patients with tracheal cancer is still poor. Few are diagnosed in the early stage and thus most are not eligible for curative treatment, mainly surgery. An increased awareness and diagnosis in the earlier stage is crucial., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.)

Aims: Despite increasing use of implantable cardioverter-defibrillators (ICDs) and reports linking selected bio-implants with cancer, the cancer risk associated with implanted ICDs remains unknown. The objective of our study was to examine cancer risk among ICD recipients., Methods and Results: We conducted a population-based cohort study using medical registries covering the entire Danish population. We identified all first-time ICD recipients during the period of 2000-11 and determined their subsequent cancer incidence. Standardized incidence ratios (SIRs) were computed by comparing observed cancer incidence in the ICD cohort with expected cancer incidence based on national incidence rates according to age, sex, and year of diagnosis. A total of 6723 ICD recipients were followed for up to 12 years (median 2.8 years) and contributed a total of 23 254 person-years of follow-up. Compared with the general population, ICD recipients had a slightly elevated overall risk of cancer [SIR = 1.1 (95% confidence interval (CI): 1.0-1.2)]. This was driven by the cancer risk among patients with ischaemic heart disease (IHD) [SIR = 1.1 (95% CI: 1.0-1.3)], which, as expected, was particularly elevated for tobacco-related cancers [SIR = 1.4 (95% CI: 1.2-1.6)]. Importantly, ICD recipients without IHD were not at increased cancer risk [SIR = 1.0 (95% CI: 0.8-1.3)]., Conclusion: This nationwide population-based cohort study with up to 12-year follow-up did not indicate a causal relation between ICD implantation and cancer. However, more follow-up data are needed to entirely rule out risks for individual cancer types., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.)

Background: Data concerning incidence and prevalence of cancer in the different regions of Russia have traditionally not been provided on a basis that facilitated comparison with data from countries in western parts of Europe. The oncological hospital in Arkhangelsk, in co-operation with Universitetet i Tromsø (Norway), has established a population based cancer registry for Arkhangelskaja Oblast (AO). AO is an administrative unit with 1.3 million inhabitants in northwestern Russia. The aim of this investigation was to assess the content and quality of the AO cancer registry (AKR), and to present the site-specific cancer-incidence rates in AO in the period 1993-2001., Methods: The population in this study consisted of all individuals registered as residents of AO. All new cancer cases in the period 1993-2001, registered the AKR, were included in the study (ICD-10: C00-C95, except for C77-78). The annual gender and age-group-specific population figures were obtained from the AO statistics office., Results: A total of 34,697 cases of primary cancers were included. The age-adjusted (world standard) incidence rate for all sites combined was 164/100,000 for women and 281/100,000 for men. The highest incidence was for cancer of the trachea, bronchus and lung (16.3% of all cases), whereof 88.6 % of the cases were among men. Among women, cancer of the breast constituted 15.9 percent of all cases. The age-adjusted incidences of the most frequent cancer sites among men were: lung (77.4/100,000); stomach (45.9); rectum (13.4); oesophagus (13.0); colon (12.2); bladder (11.6); and prostate cancer (11.1). Among women they were: breast (28.5); stomach (19.7); colon (12.2); and ovary cancer (9.0)., Conclusion: Our findings confirm and strengthen the indication that the incidences of stomach, larynx, liver, pancreas, prostate, colon, bladder and melanoma cancer are quite different in male populations in Russia compared to many other European countries. Among women, most major cancer types, except stomach, appear to be relatively low in Russian populations. The AKR provides quality data for estimations and insight to the cancer incidence in a northern Russian population, and we consider the reported incidence rates to reflect the cancer situation in AO well.

The cancer morbidity in the Republic of North Ossetia-Alania is still high: 248.2 (1998), 243.1 (1999) and 241.3 (2000) per 100,000. The site distribution patterns varied significantly: the leading localizations in 1991 were trachea, lungs and bronchus--32.1; breast--28.3; skin--26.5; stomach--21.2 and hemopoietic organs--18.0. By the year 2000, the situation had changed dramatically: breast--60.2; skin--33.7 and respiratory system--20.4.

This study describes the geographical variations in the incidence of, and mortality due to, the most frequent cancers in Quebec. They are breast, colon and tracheal, bronchial, and lung cancers in women and prostate, colon and trachea, bronchial and lung cancers in men. Data for the periods 1984 to 1986 and 1989 to 1991 for the whole of the Quebec Community Health Department are reviewed. A direct method of standardization, with the world population as the reference population, was used to allow comparison of geographical units. The ranking correlation method was used to test correlations for the various cancer sites. There were significant coefficients between the two periods only for lung cancer for both sexes, for both incidence and mortality. The spatial autocorrelation method was used to determine the presence or absence of a geographical configuration from the estimated rates. Moran I values were positive and significant for the two periods for lung cancer associated mortality and for the incidence of breast cancer. This implicates local factors (probably associated with lifestyle). The results for the incidence of lung cancer among men and women were similar for the period 1989 to 1991. The advantages and limitations of the methods used and also the data available are considered.

This report presents the first findings of the Murcia Cancer Registry, a population-based cancer registry set up in May 1981 in the Murcia region of southeast Spain (955,487 inhabitants). Descriptive epidemiological methods have been applied to study cancer incidence in 1982. The validity of cancer registration has been assessed for both completeness and accuracy. Altogether 1,987 cases were registered in 1982, the crude (all-ages) annual incidence rates per 100,000 being 238 in males and 179 in females. Excluding nonmelanoma skin cancer, which seems to be incompletely registered, age-standardized rates for Murcia are very similar to those of other registries in Spain in males, but lower in females. The risk was higher in males than in females for all sites and for the great majority of specific sites, especially larynx, oesophagus and bladder. The age-standardized rate for cancer of the larynx was 26 times higher in men than in women. Lung cancer was the most common cancer in males: the risk was 8 times that in females. Lung cancer rates were higher, in both males and females, than in other Spanish registries. Cancer of the larynx was the second most common site in males when either truncated rates (35-64 years) or cumulative incidence rates up to 64 years of age were used. The age-standardized rate (18 per 100,000) supports previous studies suggesting that the risk for this cancer in Spain and other Mediterranean countries is very high. The lung/larynx rate ratio in men was two. Cancer of the breast is the most common cancer among women, as in other registries in Spain and in most other countries. The age-standardized rate (29.4 per 100,000) is lower than breast cancer rates elsewhere in Spain. This difference may be partly explained by incompleteness of ascertainment in Murcia. The incidence rate for cancer of the cervix uteri was 4.9 per 100,000, excluding carcinoma in situ. Despite the limitations of the data, cervical cancer incidence in Murcia is likely to be similar to that in other regions of Spain.